Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study-Reference-Cited by-同舟云学术

Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study

Published:2018-05-23 Issue:8 Volume:7 Page:4115-4120
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Cui Pengfei¹²^ORCID,Liu Zhefeng¹,Wang Guoqiang³,Ma Junxun¹,Qian Yuanyu¹,Zhang Fan¹,Han Chun¹,Long Yaping¹,Li Ye¹,Zheng Xuan¹,Sun Danyang¹^ORCID,Zhang Jing¹,Cai Shangli³,Jiao Shunchang¹,Hu Yi¹

Affiliation:

1. First Department of Medical Oncology; Chinese PLA General Hospital; Beijing China

2. Department of Graduate Administration; Chinese PLA General Hospital; Beijing China

3. The Medical Department; 3D Medicines Inc.; Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1579/fullpdf

Reference18 articles.

1. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway;Momtaz;Pharmgenomics Pers Med,2014

2. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies;Naidoo;Ann Oncol,2015

3. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma;Sznol;J Clin Oncol,2017

4. Interstitial lung diseases in the hospitalized patient;Disayabutr;BMC Med,2015

5. Anti-PD-1-related pneumonitis during cancer immunotherapy;Nishino;N Engl J Med,2015

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities;Cancer Immunology, Immunotherapy;2024-09-05

2. Independent risk factor of drug eruption in immune checkpoint inhibitors treated liver cancer patients: high systemic immune-inflammation index;Cutaneous and Ocular Toxicology;2024-08-24

3. Clinical Features and Determinants of Disease Severity of Immune Checkpoint Inhibitor-Related Pneumonitis: A Retrospective Study;2024-04-03

4. Pulmonary toxicity of immune checkpoint immunotherapy;Journal of Clinical Investigation;2024-01-16

5. Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment;Cancer Medicine;2024-01-12